Common Contracts
7 similar Underwriting Agreement contracts by ADESTO TECHNOLOGIES Corp, 012 SMILE.COMMUNICATIONS LTD, Antares Pharma, Inc., others
4,000,000 Shares of Common Stock DIAMEDICA THERAPEUTICS INC. UNDERWRITING AGREEMENTUnderwriting Agreement • August 10th, 2020 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations • New York
DiaMedica Therapeutics Inc., a corporation organized and existing under the laws of British Columbia, Canada (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,000,000 shares (the “Firm Shares”) of its voting common shares, without par value (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 600,000 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim Securities”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
4,375,000 Shares* ADESTO TECHNOLOGIES CORPORATION Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 15th, 2017 • ADESTO TECHNOLOGIES Corp • Semiconductors & related devices • New York
Adesto Technologies Corporation, a Delaware corporation (the “Company”), proposes to issue and sell 4,375,000 shares (the “Firm Shares”) of the Company’s Common Stock, $0.0001 par value per share (the “Common Stock”), to you and to the several other Underwriters named in Schedule I hereto (collectively, the “Underwriters”), for whom you are acting as representative (the “Representative”). The Company has also agreed to grant to you and the other Underwriters an option (the “Option”) to purchase up to an additional 625,000 shares of Common Stock, on the terms and for the purposes set forth in Section 1(b) (the “Option Shares”). The Firm Shares and the Option Shares are referred to collectively herein as the “Shares.”
] Shares Adesto Technologies Corporation Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 13th, 2015 • ADESTO TECHNOLOGIES Corp • Semiconductors & related devices • New York
Adesto Technologies Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of [ ] shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional [ ] shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”
6,086,956 Shares IMMUNOMEDICS, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 22nd, 2013 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
Immunomedics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 6,086,956 shares (the “Firm Shares”) of the Company’s common stock, $0.01 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 913,044 shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”
12,500,000 Shares ANTARES PHARMA, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 4th, 2012 • Antares Pharma, Inc. • Surgical & medical instruments & apparatus • New York
The Company has prepared and filed in conformity with the requirements of the Securities Act of 1933, as amended (the “Securities Act”), and the published rules and regulations thereunder (the “Rules”) adopted by the Securities and Exchange Commission (the “Commission”) a “shelf’ registration statement on Form S-3 (No. 333-167975), which became effective as of July 21, 2010, including a base prospectus (the “Base Prospectus”) relating to common stock, preferred stock and warrants of the Company that may be sold from time to time by the Company in accordance with Rule 415 of the Securities Act, and such amendments
12,500,000 Shares ARENA PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 9th, 2009 • Arena Pharmaceuticals Inc • Pharmaceutical preparations • New York
Arena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you (the “Underwriter”), an aggregate of 12,500,000 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).
] Shares Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • October 26th, 2007 • 012 SMILE.COMMUNICATIONS LTD • Communications services, nec • New York
Prior to the execution of this Agreement, the Company was a wholly-owned subsidiary of Internet Gold-Golden Lines Ltd., a company organized under the laws of the State of Israel (the “Parent”).
